The FusionPlex Sarcoma v2 panel is a targeted next-generation sequencing (NGS) research product that expands on our FusionPlex Sarcoma panel. The updated design covers key fusions and variants in 63 genes relevant in sarcomas. FusionPlex uses RNA instead of DNA as input material, which allows for more accurate and more cost-effective fusion detection than DNA-based hybrid capture techniques. FusionPlex places gene-specific primers near known fusion breakpoints to identify RNA abnormalities with a single primer. Because FusionPlex can identify known and novel alterations with a limited number of primers, it can detect fusions more efficiently and accurately than DNA-based approaches
Comprehensive Fusion Detection
AMP chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.
Quiver® Fusion Database
Powerful fusion analysis combined with a curated database of relevant known translocations.
Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.
Simple, Lyophilized Workflow
Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turnaround time.
Input Nucleic Acid Required*
Unique Molecular On-Target %
Illumina® and Ion Torrent™
Fresh frozen and FFPE
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200ng is recommended.